Patty Baskin
Executive Editor, Neurology®
pbaskin@aan.com
(612) 928-6021
Exam: Exam 44
Issue: July 27, 2010
Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach
Upon completion of this podcast the participant will be able to:
1) State whether the MRI biomarkers and relapse rates in relapsing-remitting MS correlate with short-term disability related to MS.
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
Program Accreditation and Development Subcommittee (PADS) is responsible for reviewing and evaluating all CME programs. PADS members: Pradeep K. Sahota MD, FAAN, has nothing to disclose, Allison Brashear MD, FAAN, has received personal compensation for activities with Allergan, Merz, Ipsen and Osmotica as a consultant, has received personal compensation in an editorial capacity for Wemove, has received research support from Allergan, Merz, and Ipsen, J. Clay Goodman MD, FAAN, has nothing to disclose, Steven L. Lewis MD, FAAN, has received personal compensation in an editorial capacity for the journal Neurology, Barbara F. Westmoreland MD, FAAN, has nothing to disclose, Susan Rodmyre, has nothing to disclose.
Robert A. Gross, MD, PhD, FAAN has received research funding from the Department of the Army and UCBPharma. He is supported for educational endeavors from the University of Rochester Medical Center’s Clinical and Translational Science Award from the NIH. Dr. Gross has conducted clinical trials over the past five years funded by GlaxoSmithKline, UCB, Ortho-McNeil, Pfizer, and Marinus. He has served on the speakers’ bureaus for Abbott, UCB, and GlaxoSmithKline and has received consultant fees from GlaxoSmithKline and Harris Interactive. Since his appointment as Editor-in-Chief, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers’ bureaus. He receives an honorarium from AAN as Editor-in-Chief of Neurology.
Dr. Burns receives a stipend as Podcast Editor for Neurology® and performs EMG studies in his neuromuscular practice (30% effort). AAN staff members editing the test (P Baskin, K Sasik, M Petrovick, K Wiersma) have no disclosures. The CME Journal Editors, who have reviewed the exam, are Steven Lewis MD, who has no disclosures, and James WM Owens Jr. MD PhD, who receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology.
Dr. Sormani serves on speakers’ bureaus for and has received funding for travel and speaker honoraria from Merck Serono, Biogen Idec, and Teva Pharmaceutical Industries Ltd.; and has served as a consultant for Actelion Pharmaceuticals Ltd, Merck-Serono, Eidetica, and Biogen Idec.
Dr. Keegan serves as Neurology Clinical Pathological Conference Section Co-Editor for Neurology® and on the Neurology Podcast Panel.
Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section.
Dr. Cartwright receives research support from the NIH (1K23 N5062892-01A1) and has received speaker honoraria from AANEM and ASN annual meetings.
The other participants had nothing to disclose.
CME expires three years after publication date or sooner if podcasts are deemed out of date by reviewers.
The American Academy of Neurology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Neurology designates that participants will receive 0.5 AMA PRA Category 1 CME credits™ by answering the multiple-choice questions in the online Podcast quiz.
The American Academy of Neurology holds copyright for all materials in this exam.
Any information regarding the identity of individuals taking the exam or their exam scores will be kept confidential.
A computer with a web browser such as Internet Explorer, Firefox, Safari, or Google Chrome is required.